{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Extrahepatic+Bile+Duct+Cancer&page=2",
    "query": {
      "condition": "Extrahepatic Bile Duct Cancer",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Extrahepatic+Bile+Duct+Cancer&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T13:23:45.182Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00019474",
      "title": "Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Extrahepatic Bile Duct Cancer",
        "Gastric Cancer",
        "Gastrointestinal Carcinoid Tumor",
        "Liver Cancer",
        "Pancreatic Cancer",
        "Small Intestine Cancer"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "recombinant interferon alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "hydroxyurea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Montefiore Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 60,
      "start_date": "1998-03",
      "completion_date": "2000-08",
      "has_results": false,
      "last_update_posted_date": "2018-09-14",
      "last_synced_at": "2026-06-10T13:23:45.182Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00019474"
    },
    {
      "nct_id": "NCT03267940",
      "title": "Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cholangiocarcinoma Non-resectable",
        "Cholangiocarcinoma, Intrahepatic",
        "Cholangiocarcinoma, Extrahepatic",
        "Gallbladder Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "PEGPH20",
          "type": "DRUG"
        },
        {
          "name": "CIS",
          "type": "DRUG"
        },
        {
          "name": "GEM",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Halozyme Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2017-10-02",
      "completion_date": "2019-11-11",
      "has_results": true,
      "last_update_posted_date": "2020-02-07",
      "last_synced_at": "2026-06-10T13:23:45.182Z",
      "location_count": 26,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Duarte, California + 22 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03267940"
    },
    {
      "nct_id": "NCT00005997",
      "title": "Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Extrahepatic Bile Duct Cancer",
        "Gallbladder Cancer",
        "Liver Cancer"
      ],
      "interventions": [
        {
          "name": "becatecarin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "1999-04",
      "completion_date": "2005-11",
      "has_results": false,
      "last_update_posted_date": "2010-06-11",
      "last_synced_at": "2026-06-10T13:23:45.182Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Cleveland, Ohio • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005997"
    },
    {
      "nct_id": "NCT00005842",
      "title": "Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tipifarnib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2000-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-11",
      "last_synced_at": "2026-06-10T13:23:45.182Z",
      "location_count": 2,
      "location_summary": "Fort Sam Houston, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Fort Sam Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005842"
    },
    {
      "nct_id": "NCT00987766",
      "title": "Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Extrahepatic Bile Duct Cancer",
        "Gallbladder Cancer",
        "Liver Cancer",
        "Pancreatic Cancer",
        "Periampullary Adenocarcinoma",
        "Small Intestine Cancer"
      ],
      "interventions": [
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2009-11",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-06-10T13:23:45.182Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00987766"
    },
    {
      "nct_id": "NCT00085410",
      "title": "Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Extrahepatic Bile Duct",
        "Adenocarcinoma of the Gallbladder",
        "Advanced Adult Primary Liver Cancer",
        "Gastrointestinal Cancer",
        "Localized Unresectable Adult Primary Liver Cancer",
        "Recurrent Adult Primary Liver Cancer",
        "Recurrent Extrahepatic Bile Duct Cancer",
        "Recurrent Gallbladder Cancer",
        "Unresectable Extrahepatic Bile Duct Cancer",
        "Unresectable Gallbladder Cancer"
      ],
      "interventions": [
        {
          "name": "bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2004-01",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-06-10T13:23:45.182Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00085410"
    },
    {
      "nct_id": "NCT00084942",
      "title": "Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Extrahepatic Bile Duct Cancer",
        "Gallbladder Cancer"
      ],
      "interventions": [
        {
          "name": "capecitabine",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2002-10",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2012-01-12",
      "last_synced_at": "2026-06-10T13:23:45.182Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00084942"
    },
    {
      "nct_id": "NCT02012699",
      "title": "Integrated Cancer Repository for Cancer Research",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pancreatic Cancer",
        "Thyroid Cancer",
        "Lung Cancer",
        "Esophageal Cancer",
        "Thymus Cancer",
        "Colon Cancer",
        "Rectal Cancer",
        "Gastrointestinal Stromal Tumors",
        "Anal Cancer",
        "Bile Duct Cancer",
        "Duodenal Cancer",
        "Gallbladder Cancer",
        "Gastric Cancer",
        "Liver Cancer",
        "Small Intestine Cancer",
        "Peritoneal Surface Malignancies",
        "Familial Adenomatous Polyposis",
        "Lynch Syndrome",
        "Bladder Cancer",
        "Kidney Cancer",
        "Penile Cancer",
        "Prostate Cancer",
        "Testicular Cancer",
        "Ureter Cancer",
        "Urethral Cancer",
        "Hypopharyngeal Cancer",
        "Laryngeal Cancer",
        "Lip Cancer",
        "Oral Cavity Cancer",
        "Nasopharyngeal Cancer",
        "Oropharyngeal Cancer",
        "Paranasal Sinus Cancer",
        "Nasal Cavity Cancer",
        "Salivary Gland Cancer",
        "Skin Cancer",
        "Central Nervous System Tumor",
        "Central Nervous System Cancer",
        "Mesothelioma",
        "Breast Cancer",
        "Leukemia",
        "Melanoma",
        "Sarcoma",
        "Unknown Primary Tumor",
        "Multiple Myeloma",
        "Ovarian Cancer",
        "Endometrial Cancer",
        "Vaginal Cancer",
        "Neuroendocrine Tumors",
        "Plasma Cell Dyscrasia",
        "Healthy Control"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "110 Years",
        "sex": "ALL",
        "summary": "19 Years to 110 Years"
      },
      "enrollment_count": 999999,
      "start_date": "2013-11-01",
      "completion_date": "2099-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-06-10T13:23:45.182Z",
      "location_count": 42,
      "location_summary": "Greenwood Village, Colorado • Manchester, Connecticut • Daytona Beach, Florida + 34 more",
      "locations": [
        {
          "city": "Greenwood Village",
          "state": "Colorado"
        },
        {
          "city": "Manchester",
          "state": "Connecticut"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Orange City",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02012699"
    },
    {
      "nct_id": "NCT00021047",
      "title": "Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Esophageal Cancer",
        "Extrahepatic Bile Duct Cancer",
        "Gastric Cancer",
        "Head and Neck Cancer",
        "Liver Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "capecitabine",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "epirubicin hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2001-07",
      "completion_date": "2004-06",
      "has_results": false,
      "last_update_posted_date": "2012-03-08",
      "last_synced_at": "2026-06-10T13:23:45.182Z",
      "location_count": 3,
      "location_summary": "Bethesda, Maryland • Portsmouth, Virginia",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Portsmouth",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00021047"
    },
    {
      "nct_id": "NCT01640522",
      "title": "Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hepatocellular Carcinoma",
        "Primary Liver Cancer",
        "Bile Duct Cancer",
        "Pancreatic Cancer",
        "Gallbladder Cancer",
        "Colorectal Carcinoma",
        "Liver Metastases"
      ],
      "interventions": [
        {
          "name": "Collaborative Care",
          "type": "OTHER"
        },
        {
          "name": "Enhanced usual Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 261,
      "start_date": "2008-01",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2024-12-13",
      "last_synced_at": "2026-06-10T13:23:45.182Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01640522"
    }
  ]
}